Compare Marriott International Inc (MAR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs ResMed Inc. — how do they compare? Marriott International Inc trades at $360.95 (market cap $92.96B), while ResMed Inc. trades at $225.92 (market cap $31.78B). The key difference: Marriott International Inc is far larger — about 2.9× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and ResMed Inc. for 51 Days on average.
| MAR | RMD | |
|---|---|---|
Market Cap | $92.96B | $31.78B |
Volume | 1,173,633 | 1,128,382 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $277.88 |
52-Week Low | $259.04 | $182.82 |
Typical Hold Time | 164 Days | 51 Days |
Enterprise Value | $110.28B | $31.14B |
Dividend Yield | 0.82% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $361.08, showing minimal daily movement with a slight decline of 0.06%. The stock maintains a bullish technical signal with strong moving average support and trades near key resistance at $360. Fundamentally, the company reported solid Q2 2026 earnings beat with $3.19 EPS versus $3.08 expected, continuing revenue growth to $26.19B in 2025, though valuation ratios remain elevated with P/E at 36.9. Recent developments include new technology partnerships and upcoming dividend payment.
Marriott presents a mixed investment case with strong operational performance offset by high valuation multiples. The consensus price target of $386.71 suggests 7% upside potential, supported by 44% analyst buy ratings. Key risks include rising debt levels with debt-to-asset ratio reaching 58.83% and potential travel sector volatility. The company's dominant market position and continued travel demand provide growth catalysts, but investors should weigh valuation concerns against fundamental strength.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
